Roche Molecular Systems Inc.
PLEASANTON, California, July 22, 2011 -
- cobas KRAS
Mutation Test identifies colorectal cancer patients not likely to
respond to anti-EGFR antibody therapies.
PLEASANTON, California, October 11, 2010 - Roche Molecular Systems, Inc.
PLEASANTON, California, July 8, 2010 - Roche Molecular Systems, Inc.
PLEASANTON, California, December 9 - Roche Molecular Systems, Inc.
PLEASANTON, California, December 2 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the United States
Food & Drug Administration (FDA) approved an additional intended use for its
licensed nucleic acid test, to screen source plasma in pools comprised of up
to 96 individual donations.
